NATCO Pharma is investing $14 million in eGenesis, Inc. through its wholly owned subsidiaries, NATCO Pharma (Canada) Inc. for an amount of $9.5 million and NATCO Pharma South Africa Proprietary for an amount of $4.5 million, though convertible promissory notes. Previously in 2024, NATCO Pharma had invested $8 million in eGenesis, Inc. through preferred stock. The total investment made by NATCO Pharma in eGenesis, Inc. now stands at $22 million.
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure.
NATCO Pharma develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1899.10 |
| Dr. Reddys Labs. | 1158.00 |
| Cipla | 1380.55 |
| Lupin | 2110.00 |
| Zydus Lifesciences | 1129.10 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: